Previous close | 0.7500 |
Open | 0.7300 |
Bid | 1.1000 |
Ask | 2.0000 |
Strike | 240.00 |
Expiry date | 2024-06-21 |
Day's range | 0.7300 - 1.2500 |
Contract range | N/A |
Volume | |
Open interest | 1.24k |
SOD1-ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS estimated to affect less than 1,000 people in Europe1QALSODY is Biogen’s third rare disease therapy to be approved in the EU, demonstrating the company’s commitment to addressing diseases with a high unmet needWith QALSODY, Biogen has helped advance neurofilament as a tool to optimize clinical trial design in ALS, offering the potential to expedite further breakthroughs in the field CAMBRIDGE, Mass., May 30, 2024 (GLO
Eli Lilly stock broke out after the company reported positive results for Crohn's disease drug. Is LLY stock a buy right now?
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.